Alec­tor cuts 11% of work­force as it dou­bles down on late-stage neu­ro pro­grams part­nered with GSK, Ab­b­Vie

A month af­ter re­veal­ing plans to con­cen­trate on its late-stage im­muno-neu­rol­o­gy pipeline, Alec­tor is trim­ming its head­count by 11%.

The lay­offs will im­pact around 30 em­ploy­ees across the or­ga­ni­za­tion, the com­pa­ny dis­closed in an SEC fil­ing, adding that the plan will “bet­ter align the com­pa­ny’s re­sources” with the new strat­e­gy. With $712.9 mil­lion in cash, cash equiv­a­lents and in­vest­ments as of the end of 2022, Alec­tor be­lieves the re­serves will now get it through 2025.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER